Stay updated with breaking news from Generation Ipsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Total-sales growth in FY 2023 of 6.7% at CER1 included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% , based on further...
PARIS, FRANCE, 7 December 2023 - Ipsen , a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our...
On the occasion of its Investor Day, Ipsen said it was aiming for average growth in total sales of at least 7% a year for the period 2023-27 at constant exchange rates, and an operating margin from...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results